Clinical Trials Logo

Atypical Parkinsonism clinical trials

View clinical trials related to Atypical Parkinsonism.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06122662 Recruiting - Clinical trials for Neurodegenerative Diseases

AMX0035 and Progressive Supranuclear Palsy

ORION
Start date: December 21, 2023
Phase: Phase 3
Study type: Interventional

ORION Trial is a trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of a randomized double blind placebo controlled phase, followed by an optional open-label extension phase.

NCT ID: NCT05792332 Recruiting - Clinical trials for Nurse-Patient Relations

Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing (IMPACT Study)

Start date: August 17, 2023
Phase: N/A
Study type: Interventional

This project aims to investigate whether an integrated model based on proactive and reactive telenursing monitoring coordinated by a parkinsonism nurse specialist (case manager) is able to improve care delivery and quality of life of patients with atypical parkinsonisms. This could reduce the risk (e.g. through health education counselling) and the severity of complications (e.g. falls). Main responsibilities of the Co-PI: project idea and supervision, coordination of the study, patient selection and recruitment, patient recruitment, participation in statistical analysis and drafting the manuscript. Co-PI is responsible of the rate of recruitment and drop-out

NCT ID: NCT03924414 Recruiting - Parkinson Disease Clinical Trials

Trial of Parkinson's And Zoledronic Acid

TOPAZ
Start date: November 15, 2019
Phase: Phase 4
Study type: Interventional

This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.

NCT ID: NCT03368300 Recruiting - Clinical trials for Atypical Parkinsonism

Epidemiology and Pathophysiology of Parkinsonism in the Caribbeans

CAP
Start date: August 3, 2012
Phase: N/A
Study type: Interventional

The primary aim of this study is to estimate the frequency and to characterize clinically atypical parkinsonism in the French West Indies and Guyana.

NCT ID: NCT03079310 Recruiting - Parkinson Disease Clinical Trials

Spinal Cord Stimulation for Gait in Parkinson Disease

Start date: February 2016
Phase: N/A
Study type: Interventional

Balance and gait impairment increases the risk of falls and contributes to a reduced quality of life and shorter survival in Parkinson disease (PD) and atypical Parkinsonism patients. In preliminary case studies, electrical epidural spinal cord stimulation (SCS) has been shown to significantly improve gait, postural instability, rigidity, and tremor. Controlled studies for optimizing which stimulation settings produce the best clinical response for mobility and gait, and achieving these results chronically are all significant unmet needs. Using quantitative laboratory and mobile technologies to test a range of stimulation settings, this research study aims to determine which SCS parameters or combination of parameters is best suited to effectively alleviate disabling symptoms experienced by each patient.

NCT ID: NCT01249768 Recruiting - Parkinson's Disease Clinical Trials

Parkinson's Disease, Diagnostic Observations (PADDO)

PADDO
Start date: July 2010
Phase: N/A
Study type: Observational

Background: Parkinson's Disease and the Atypical Parkinsonian Disorder (like Multiple System Atrophy, Progressive Supranuclear Palsy, Corticobasal Degeneration, Lewy Body Dementia) are disease entities with partly common symptomatology. Especially very early in the course of disease, the differentiation between both disease entities can be challenging, even for specialists in the field of movement disorder. However, the establishment of a correct diagnosis is very important for adequate patientcounseling, treatment and the correct inclusion of patients in research trials. Ancillary diagnostic investigations are looked upon to aid in this diagnostic dilemma. Objective: To investigate the value of ancillary diagnostic investigations, more specific MRI, analysis of cerebrospinal fluids and a second opinion in a specialized movement disorder centre, to differentiate Parkinson's disease and the Atypical Parkisonisonian disorder.